#USA #Cambridge #biotechnology #NeuroSense #NRSN

NeuroSense Provides Update on Nasdaq Listing Compliance

NeuroSense Therapeutics Ltd., a Cambridge-based clinical biotechnology company focused on innovative treatments for neurodegenerative diseases, has recently announced crucial developments regarding its listing status on the Nasdaq Stock Market. As of October 1, 2026, the company received a letter from the Listing Qualifications Department concerning its compliance with Nasdaq's financial requirements.

Key Compliance Issues

The primary concern raised in the letter involves NeuroSense's failure to meet Nasdaq's requirement of maintaining a minimum market value of listed securities (MVLS) of $35 million. The company was under scrutiny as it had been below this threshold for 30 consecutive trading days. In accordance with Nasdaq regulations, NeuroSense was granted a 180-day grace period to regain compliance, which expired on September 29, 2026. Since the company did not meet the threshold by the deadline, its shares are at risk for delisting unless an appeal is successfully lodged.

In response, NeuroSense plans to appeal the Staff Determination, aiming to present its case before a Nasdaq Hearings Panel. This hearing process would place a temporary hold on the delisting until the panel reaches a decision. The company is hopeful of receiving an additional period, potentially up to 180 days, to align with Nasdaq's continued listing requirements.

Regained Bid Price Compliance

On a more positive note, NeuroSense also reported that it has complied with Nasdaq's minimum bid price requirement, which dictates that listed currencies must maintain a bid price of at least $1.00 per share. Following a strategic 1-for-20 reverse share split undertaken by the company, the bid price has remained above the required threshold for a stretch of 10 consecutive business days from September 15 to September 28, 2026. This development confirmed the closure of the matter surrounding the bid price compliance.

Alon Ben-Noon, CEO of NeuroSense, expressed optimism about regaining compliance and stated, "Meeting the minimum bid price requirement is an essential milestone. Now, we look forward to sharing our plan with the Hearings Panel to address Nasdaq's remaining listing requirements."

Future Plans for NeuroSense

NeuroSense is currently focused on advancing its lead product, PrimeC, a novel oral therapy aimed primarily at treating amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The company is gearing up for its Phase 3 PARAGON trial for ALS and finalizing its New Drug Submission to Health Canada, demonstrating its commitment to bringing valuable treatments to market.

With the successful completion of the long-term follow-up data analysis from its previous Phase 2b PARADIGM study in ALS—where the results indicated a slower functional decline in patients treated with PrimeC versus those receiving placebo—the company is poised for significant advancements.

Looking Ahead

Despite the challenges regarding its Nasdaq compliance, NeuroSense remains steadfast in its mission to enhance treatment options for neurodegenerative diseases. The appeal process is a critical step in maintaining its public listing, which will provide the necessary visibility and financial backing needed for further development. Stakeholders and investors will be keeping a close eye on the situation as the company navigates these regulatory waters while continuing to push forward with its research and clinical trials.

For more information on the latest updates, you can visit NeuroSense's website or follow their journey on social media. The excitement continues as stakeholders eagerly await what comes next for this innovative biotechnology company.